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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is considered the liver component of
the metabolic syndrome. We investigated the diastolic and systolic functional parameters of
patients with NAFLD and the impact of metabolic syndrome on these parameters.
Methods: Thirty-five non-diabetic, normotensive NAFLD patients, and 30 controls, were
included in this study. Each patient underwent transthoracic conventional and tissue Doppler
echocardiography (TDI) for the assessment of left ventricular (LV) diastolic and systolic func-
tion. Study patients were also evaluated with 24-hour ambulatory blood pressure monitoring.
Results: NAFLD patients had higher blood pressures, increased body mass indices, and more
insulin resistance than controls. TDI early diastolic velocity (E’ on TDI) values were lower in
NAFLD patients than the controls (11.1 ± 2.1 vs 15.3 ± 2.7; p < 0.001). TDI systolic velocity
(S’ on TDI) values were lower in NAFLD patients than the controls (9.34 ± 1.79 vs 10.6 ± 1.52;
p = 0.004). E’ on TDI and S’ on TDI values were moderately correlated with night-systolic
blood pressure, night-diastolic blood pressure, and night-mean blood pressure in NAFLD patients.
Conclusions: Patients with NAFLD have impaired LV systolic and diastolic function even in
the absence of morbid obesity, hypertension, or diabetes. (Cardiol J 2010; 17, 5: 457–463)
Key words: left ventricular function, non-alcoholic fatty liver disease,
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is
the commonest cause of chronic liver disease [1, 2]
and is associated with significant liver-related mor-
bidity and mortality in population-based studies [3].
NAFLD is usually associated with obesity [4, 5],
diabetes [6–8], dyslipidemia [6, 9–11], and insulin
resistance [11–15]. NAFLD is the hepatic manifes-
tation of the metabolic syndrome.
Metabolic syndrome is prevalent in the gener-
al population (approximately 22%) and is associat-
ed with increased cardiovascular morbidity and
mortality [16, 17]. Recent studies have demonstra-
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ted a high prevalence of left ventricular (LV) remo-
deling and diastolic dysfunction in patients with me-
tabolic syndrome [18–21]. However, these studies
included patients with obesity and/or hypertension
which are independent risk factors for diastolic dys-
function. Therefore, it is unclear whether impaired
diastolic function and the changes in the cardiac
structure are the consequence of hypertension and/
/or obesity or the effect of insulin resistance on the
myocardium [22–24]. Currently, there are scarce
data on alterations in LV structure and function in non-
-diabetic, normotensive patients with metabolic syn-
drome. In this study, we investigated LV systolic
and diastolic function with echocardiography in nor-
motensive, non-diabetic patients with NAFLD.
Methods
Thirty-five patients who were diagnosed with
NAFLD by abdominal ultrasonography, and
30 healthy controls, were included in this study.
The control group had completely normal ultrasono-
graphic findings of the liver. Patients were conse-
cutively enrolled from hospital admissions between
December 2007 and April 2008. Patients with high
blood pressure during the enrollment (mean value
of three consecutive measurements done at five
minute intervals ≥ 140/90 mm Hg) or those on any
antihypertensive medication or with a high fasting
blood glucose level (≥ 110 mg/dL) were excluded
from the study. The following subjects were also
excluded from this study: patients with diabetes
mellitus, hypertension, severe morbid obesity
[body mass index (BMI) > 35], stage > three chro-
nic kidney disease, moderate or severe heart valve
insufficiency, congenital heart disease, atrial fibril-
lation, established coronary artery disease (CAD),
(patients who had history of myocardial infarction,
unstable angina pectoris, angiographically proven
significant coronary stenosis or had undergone
revascularization), left ventricular ejection fraction
< 40%, symptomatic heart failure, hemachromato-
sis, alpha1-antitrypsin deficiency, Wilson’s disease,
or autoimmune liver disease. In addition, patients
with a history of chronic alcoholism or alcohol con-
sumption greater than 200 g/week, with hepatitis B
or C, or on medications that might affect liver func-
tion tests were excluded from the study. Subjects
who refused to participate in the study were also
excluded. All subjects gave informed consent and the
study was approved by the local ethics committee.
Currently, abdominal ultrasound is the pre-
ferred method for qualitative assessment of fatty
infiltration of the liver. All study subjects underwent
abdominal ultrasonography using a GE Logiq 500
device with a 7 MHz linear transducer (GE Medi-
cal Systems, Milwaukee, Wisconsin, USA). We used
Hamaguchi et al’s [25] scoring system based on
hepatorenal echo contrast, liver brightness and deep
attenuation, and vascular blurring criteria was used
for the evaluation of NAFLD. Patients with a score
≥ 2 were labeled as NAFLD, and those with a score
of zero were included in the control group.
All study patients underwent a thorough clini-
cal, anthropometric, and laboratory investigation.
Laboratory tests included hepatitis serology, liver
function tests, fasting lipid profile, plasma glucose,
insulin, and C-peptide. Insulin resistance (IR) was
estimated using the homeostasis model assessment
(HOMA-IR) according to the formula: HOMA-
-Index = fasting blood glucose [mg/dL] × immu-
noreactive insulin [µU/mL]/405 [26].
The height and weight of all subjects were
measured and the BMI was calculated as weight
[kg] divided by height2 [m]. Waist circumference
(WC; at the nearest half centimeter) was measured
at the mid-point between the lower border of the
rib cage and the iliac crest.
The echocardiographic examinations and the
ambulatory blood pressure (BP) monitoring were
performed on the same day for each patient. Twen-
ty-four-hour ambulatory blood pressure monitoring
(ABPM) was performed with a non-invasive record-
er Tracker NIBP2 (Del Mar Reynolds Medical Ltd.,
Hertford, UK). Blood pressure readings were obtained
automatically at 15 minute intervals from 6 am to
11 pm and at 30 minute intervals from 11 pm to 6 am.
Average diastolic (DBP) and systolic (SBP) blood
pressure over 24 hours, and average daytime and
nighttime BP were calculated.
Echocardiographic measurements
All echocardiographic and Doppler assesses-
ments were performed by one operator, who was
blinded for the clinical and laboratory results of the
study group. Vivid 7 Dimension echocardiography
equipment (GE, Vingmed, Horten, Norway) with
a 2.5 MHz phased-array transducer was used for
each study subject. Left ventricular dimension and
wall thickness was measured from two-dimensio-
nal guided M-mode echocardiographic tracings at
mid-chordal level on the parasternal long axis view.
The M-mode traces were recorded at a speed of
50 mm/s. Ejection fraction was calculated using the
Teicholz formula. The left ventricular mass (LVM)
was estimated by using the anatomically validated for-
mula of Devereux et al. [27]. It was indexed for body
surface area to estimate the LVM index (LVMI).
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From the apical four-chamber view, pulse-wave
Doppler recordings of the mitral inflow were ob-
tained with the sample volume placed at the tips of
the mitral valve leaflets. The following parameters
were measured by pulse-wave Doppler: peak ve-
locities of early (E) and late diastolic filling (A),
deceleration time (DT), isovolumic relaxation time
(IVRT). The ratio of early diastolic to late diastolic
mitral inflow velocities was calculated (E/A).
The tissue Doppler echocardiography (TDI)
program was set to pulse-wave Doppler mode. Fil-
ters were set to exclude high frequency signals.
Gains were minimized to allow a clear tissue signal
with minimal background noise. The TDI of the
diastolic velocities was obtained from the apical
four-chamber view. A 1.5-mm sample volume was
placed at the lateral corner of the mitral annulus.
Analysis was performed for early (E’) and late diastolic
velocity (A’) and systolic velocity (S’). In addition,
E/E’ was calculated as another indicator of diastolic
function. All Doppler signals were recorded with
a chart recorder set at 100 mm/s. The averages
of three cycles were used.
Statistical analysis
All statistical analyses were performed by
SPSS for Windows, version 13.0 (SPSS Inc, Chica-
go, Illinois, USA). The two-tailed unpaired Student
t-test or Mann-Whitney U test was used to com-
pare the NAFLD group with the control group. The
correlations between the parametric variables were
investigated by Pearson correlation analysis. The
categorical variables of the groups were compared
by Pearson c2 test. A p value < 0.05 was accepted
as statistically significant in all analyses.
Results
Thirty-five NAFLD patients (mean age 41.4 ±
± 6.2 years) and 30 controls (mean age 39.2 ± 6.0
years) were included in this study. The clinical and
biochemical characteristics of the study population
are reported in Table 1. The two groups were sim-
ilar in age, gender, total cholesterol, low density
lipoprotein (LDL)-cholesterol, and alkaline phos-
phatase (ALP) levels. The BMI values and WC of
the NAFLD patients were significantly higher than
the controls (30.4 ± 3.4 vs 25.2 ± 1.6 kg/m2, p < 0.01,
and 106.9 ± 8.9 vs 92.6 ± 6.9 cm, p < 0.01, respec-
tively). Fasting glucose, triglyceride, very low den-
sity lipoprotein (VLDL), aspartic acid transaminase
(AST), alanine transaminase (ALT), fasting insulin,
C-peptide, and HOMA-IR levels in the NAFLD pa-
tients were significantly higher than in the control
group. High density lipoprotein (HDL)-cholesterol
levels were lower in NAFLD patients than controls.
Eleven (31.4%) patients with NAFLD had low HDL
[< 40 mg/dL (male), < 50 mg/dL (female)]; four
(13.3%) control subjects had a low HDL. The BMI
values of NAFLD patients were: one (2.8%) patient
Table 1. Clinical and biochemical characteristics of the study population.
Variables NAFLD-patients (n = 35) Controls (n = 30) P
Age (years) 41.40±6.25 39.20±6.04 0.156
Sex (female) 14 (40%) 13 (43.3%) 0.545
Body mass index [kg/m2] 30.44±3.45 25.20±1.63 < 0.001
Waist circumference [cm] 106.97±8.99 92.67±6.95 < 0.001
Fasting glucose [mg/dL] 97.94±11.46 90.73±5.91 0.003
Total cholesterol [mg/dL] 210.06±41.16 199.93±30.15 0.269
LDL-cholesterol [mg/dL] 128.49±32.59 129.13±27.38 0.932
HDL-cholesterol [mg/dL]  43.11±7.89 46.87±6.30 0.040
Triglycerides [mg/dL] 194.54±94.38 111.07±43.85 < 0.001
VLDL [mg/dL] 38.86±18.80 22.40±8.81 < 0.001
AST [U/L] 33.23±13.33 23.07±5.82 < 0.001
ALT [U/L] 66.57±36.79 28.47±12.89 < 0.001
ALP [U/L] 188.51±48.65 195.40±35.29 0.522
Fasting insulin [µU/mL] 14.75±5.72 5.73±1.23 < 0.001
C-peptide [ng/mL]  3.34±1.28 1.74±0.44 < 0.001
HOMA-IR  3.59±1.51 1.28±0.29 < 0.001
NAFLD — non-alkoholic fatty liver disease; LDL — low density lipoprotein; HDL — high density lipoprotein; VLDL — very low density lipoprotein;
AST — aspartic acid transaminase; ALT — alanine transaminase; ALP — alkaline phosphatase
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had BMI < 25 kg/m2, 15 (42.9%) patients had BMI
25–29.9 kg/m2, and 19 (54.3%) patients had BMI
> 30 kg/m2. Ten (33.3%) control subjects had BMI
< 25 kg/m2 and the remaining 20 (66.6%) control
subjects had BMI 25–29.9 kg/m2. Twenty-two
(62.8%) NAFLD patients had a triglyceride level
higher than 150 mg/dL, compared to six (20%) con-
trols (p < 0.01).
Thirty-one (88.6%) patients with NAFLD had
an increased WC [> 94 cm (male), > 80 cm (fe-
male)]; 14 (46.6%) control subjects had an increased
WC. Although the patients in the NAFLD group
were normotensive and non-diabetic, 11 patients
(31.4%) had the metabolic syndrome, whereas no
control subjects had the metabolic syndrome.
The office and ambulatory blood pressure pa-
rameters of the groups are reported in Table 2. All
parameters, with the exception of the office DBP
and the night SBP, were higher in NAFLD patients
than in the controls.
The echocardiographic characteristics of the
patients are reported in Table 3. Ventricular dimen-
sion, left atrium size and ejection fraction of the two
groups were similar. However, interventricular
septum wall thickness, posterior wall thickness,
LVM, and LVMI values were higher in NAFLD
patients than in the controls. S’ on TDI values were
lower in NAFLD patients than the controls (9.34 ±
± 1.8 vs 10.6 ± 1.5; p = 0.004).
Diastolic function parameters were significant-
ly different in NAFLD patients (Table 4). Although
the peak velocities of early (E) and late diastolic fill-
ing (A) were similar, E/A ratio was lower in NAFLD
patients than the controls. NAFLD patients had in-
creased DT and IVRT compared to the controls.
E’ on TDI values was lower in NAFLD patients than
the controls (11.1 ± 2.1 vs 15.3 ± 2.7; p < 0.001).
The indicator of LV filling pressure (E/E’) was high-
er in NAFLD patients than the controls (6.64 ± 1.39
vs 4.91 ± 0.91; p < 0.001).
Table 2. Ambulatory blood pressure parameters of the study patients.
Parameters NAFLD-patients (n = 35) Controls (n = 30) P
Office SBP [mm Hg] 127.83±9.14 121.93±9.33 0.013
Office DBP [mm Hg] 79.40±6.67 75.93±7.39 0.051
24 h-SBP [mm Hg] 125.97±9.25 120.93±8.33 0.025
24 h-DBP [mm Hg] 78.03±5.74 73.40±6.36 0.003
24 h-MBP [mm Hg] 88.11±6.10 83.53±7.02 0.006
Day-SBP [mm Hg] 130.69±10.84 125.00±9.21 0.027
Day-DBP [mm Hg] 81.31±7.22 76.67±7.06 0.011
Day-MBP [mm Hg] 91.83±7.59 86.67±7.58 0.008
Night-SBP [mm Hg] 114.34±9.04 110.80±7.00 0.086
Night-DBP [mm Hg] 69.09±6.81 65.07±6.10 0.016
Night-MBP [mm Hg] 78.69±6.91 74.93±6.10 0.025
NAFLD — non-alkoholic fatty liver disease; SBP — systolic blood pressure; DBP — diastolic blood pressure; MBP — mean blood pressure
Table 3. Echocardiographic characteristics of the patients
Parameters NAFLD-patients (n = 35) Controls (n = 30)  P
IVS [cm] 0.98±0.08 0.79±0.07 < 0.001
PW [cm] 0.93±0.09 0.75±0.07 < 0.001
LVESD [cm] 3.19±0.34 3.18±0.23 0.913
LVEDD [cm] 4.87±0.48 4.76±0.25 0.243
EF (%) 63.40±4.16 62.47±4.31 0.379
LVM [g] 169.83±39.81 114.77±16.43 < 0.001
LVMI [g/m3] 82.06±16.88 59.17±8.75 < 0.001
LA [cm] 3.68±0.39 3.53±0.34 0.113
S’ [cm/s] 9.34±1.8 10.6±1.5 0.004
NAFLD — non-alkoholic fatty liver disease; IVS — interventricular septum diastolic thickness; PW — posterior wall diastolic thickness; LVESD — left
ventricular end-systolic diameter; LVEDD — left ventricular end-diastolic diameter; EF — ejection fraction; LVM — left ventricular mass; LVMI — left
ventricular mass index; LA — left atrial systolic diameter; S’ — systolic velocity on tissue Doppler echocardiography
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The correlation analysis
In the NAFLD patients, E’ on TDI value was
moderately correlated with night-SBP (r = –0.37,
p = 0.026), night-DBP (r = –0.49, p = 0.003),
night-MBP (r = –0.49, p = 0.003) and S’ on TDI
was correlated with night-SBP (r = –0.37, p =
= 0.028), night-DBP (r = –0.42, p = 0.012), night-
-MBP (r = –0.42, p = 0.011). However, in the con-
trol group, E’ on TDI was correlated with office-
SBP (r = –0.41, p = 0.024) and S’ on TDI was
weakly correlated with LVMI (r = –0.37, p = 0.04).
There was no significant correlation between BMI,
WC, HOMA-IR, E’ on TDI, and S’ on TDI.
Discussion
Our findings indicate that LV diastolic and
systolic function is significantly impaired in normo-
tensive, non-diabetic NAFLD patients compared to
healthy, age-matched control subjects. In addition,
the ambulatory blood pressure recordings revealed
that the patients with NAFLD had higher BP va-
lues than the controls, although they were normo-
tensive at the baseline office visit.
Most population studies assess cardiovascular
risk in terms of the manifestations of obesity, in-
cluding dyslipidemia, diabetes mellitus, and hyper-
tension. These disorders usually occur together and
are referred to as the metabolic syndrome [28, 29].
They are almost always initiated by excessive
weight gain. The risk estimates from the Framing-
ham Heart Study suggest that up to 78% of hyper-
tension in men and 65% in women can be directly
attributed to increased body weight [30]. In addi-
tion, epidemiological studies indicate that excessive
weight gain is a consistent predictor for subsequent
development of hypertension, metabolic syndrome,
and NAFLD.
Multiple mechanisms contribute to LV dys-
function in obesity, including lipotoxicity associat-
ed with cardiac steatosis and lipoapoptosis, altera-
tions in fatty acid metabolism, overproduction of
cardioinhibitory cytokines, up-regulation of some
neurohormones (especially angiotensin II), myocar-
dial fibrosis and chronic overload with LV dilatation
and hypertrophy, and increased oxygen consump-
tion [31–33]. Insulin resistance may represent a link
between obesity and LV dysfunction. Elevated in-
sulin levels in patients with IR stimulate myocyte
growth and interstitial fibrosis. Insulin also causes
sodium retention and activates the sympathetic
nervous system which can affect cardiac perform-
ance [32, 33]. Moreover, alterations in myocardial
metabolism, including progressive increases in fat-
ty acid turnover, may impair LV contractility [31].
Finally, chronic sodium retention increases BP lev-
els which in turn will cause myocardial tissue dam-
age, myocardial fibrosis, and impairment of the LV
function in response to LV pressure overload [34].
It is well-established that the metabolic syn-
drome and insulin resistance affect LV geometry
and function [35–42]. The presence of insulin re-
sistance altered the cardiac structure and contrac-
tile function at the level of the myocyte in an ani-
mal study [23]. This finding has been also demon-
strated in humans [35, 36]. Whether or not the
insulin resistance is independently associated with
cardiac remodeling is unknown. The influence of
insulin resistance on LVM has been observed in
normotensive diabetic patients. In addition, fasting
plasma insulin was found to be the strongest inde-
pendent predictor of LVM [38]. Iacobellis et al. [35]
reported that insulin resistance in obesity in the
absence of diabetes was associated with an in-
creased LVM and changes in LV geometry. How-
ever, not all studies in the non-diabetic population
Table 4. Diastolic functional parameters of the study patients.
Parameters NAFLD-patients (n = 35) Controls (n = 30) P
E [cm/s] 71.1±11.2 74.9±13.5 0.363
A [cm/s] 58.2±9.2 54.3±9.1 0.279
DT [ms] 192.8±33.4 166.7±34.2 < 0.001
IVRT [ms] 107.3±12.1 94.8±12.6 < 0.001
E/A ratio 1.25±0.28 1.42±0.34 0.028
E’ [cm/s] 11.1±2.1 15.3±2.7 < 0.001
E/E’ ratio 6.64±1.39 4.91±0.91 < 0.001
NAFLD — non-alkoholic fatty liver disease; E — early diastolic filling velocity; A — late diastolic filling velocity; DT —  deceleration time;
IVRT — isovolumic relaxation time; E’ — early diastolic velocity on tissue Doppler echocardiography
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supported their results. When adjusted for BMI and
BP, insulin resistance was not an independent de-
terminant of LVM [41].
There is limited data on the influence of the
metabolic syndrome on LV function, especially in
patients without hypertension, diabetes, and obes-
ity. A slight increase in plasma glucose levels was
associated with abnormal diastolic function, inde-
pendent from LV hypertrophy in non-diabetic pa-
tients with treated hypertension [41]. Another
study that evaluated the association of insulin re-
sistance and LV diastolic indices in uncomplicated
hypertension, demonstrated an independent asso-
ciation between the prolongation of IVRT and plas-
ma leptin levels [42]. The effect of the metabolic
syndrome on the LV diastolic function has also been
demonstrated in the Strong Heart Study [19].
Changes in LV geometry and function correlated
well with BMI in the previous studies that includ-
ed patients with marked obesity. Recently, two
studies in obese populations revealed that de-
creased systolic and early diastolic velocities on
TDI and BMI were the only predictors of LV systo-
lic and diastolic dysfunction [43, 44].
In our study, we found mild abnormalities in
the LV structure, including increased LVM, LVMI
and LV wall thickness in patients with NAFLD com-
pared to the controls. Our patients with NAFLD
were heavier than the controls, but did not have
morbid obesity. Although all of the NAFLD patients
were normotensive and non-diabetic, they had high-
er BP recordings, higher BMIs, and higher levels
of insulin resistance than the controls. The impair-
ment on systolic and diastolic function could reflect
the cumulative effect of increased weight, elevat-
ed BP, and insulin resistance. The correlation anal-
ysis revealed that night systolic, diastolic, and mean
BP levels were associated with E’ on TDI and S’
on TDI values. However, the sample size of our
study was relatively small which did not allow us
to perform multivariate analysis for determining in-
dependent predictors of LV systolic and diastolic
impairment. Although the previous studies revealed
that the NAFLD patients had impaired diastolic
function, we demonstrated the relationship between
LV functions and BP values by using ambulatory BP
monitoring [45, 46]. Therefore, we suggest that
a larger study with ABPM should be designed to
evaluate the relationship between the systolic and
diastolic functions and the BMI, HOMA, and BP le-
vels in patients with NAFLD.
Limitations of the study
The primary limitation of this study is the small
size of the study population. However, our study
included highly selected (normotensive and non-
-diabetic) patients with NAFLD. Secondly, we could
not rule out the presence of silent CAD, since we
did not evaluate the patients with stress tests or
coronary angiography prior to their enrollment.
However, the clinical, echocardiographic and elec-
trocardiographic evidence was reliable enough to
exclude patients with ischemic heart disease. Third-
ly, the BP levels of patients with NAFLD were high-
er than the control group, although both groups
were normotensive. While this population did not
have overt JNC-7 Stage 1 hypertension, the vast
majority of our patients would be diagnosed with
pre-hypertension. Given this, it is not entirely sur-
prising that the study group had a higher incidence
of subtle echocardiographic findings consistent
with LV systolic and diastolic dysfunction. Appar-
ently, we cannot state which parameter out of BP,
HOMA or BMI is associated with LV function. If
our study population had included a patient sub-
group with similar BP levels between controls and
NAFLD cases, we could have determined specifi-
cally which one out of BP, HOMA or BMI affected
LV function. We believe that our study, despite its
limitations, increases awareness of the possibility
of LV dysfunction in both NAFLD and metabolic
syndrome patients without overt hypertension.
Conclusions
In conclusion, we found that there was signifi-
cant impairment on systolic and diastolic function
in the non-diabetic and normotensive NAFLD pa-
tients compared to the controls. We suggest that
patients with NAFLD require aggressive cardiac
risk factor modification and closer follow-up for the
prevention of diastolic and systolic heart failure.
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